Journal of Clinical Microbiology · 2004 · 50 citations · 19 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAnaerobic BacteriologyAntibiotic ResistanceAntibiotic Resistance MechanismsAntimicrobial Susceptibility TestingBacterial InfectionsMechanisms Of Antimicrobial ResistanceAnaerobic Bacterial InfectionsAnaerobic Bloodstream InfectionsAnaerobic Infection TreatmentBacteroides SpeciesDrug Resistance PatternsDrug-resistant PathogensEmpirical Therapy CoverageMetronidazole Therapy
Members of the Bacteroides fragilis group are among the most common anaerobic bacterial isolates in clinical specimens. Metronidazole, a 5-nitroimidazole, is often used as empirical therapy for anaerobic infections. Susceptibility testing is not routinely performed because of nearly universal susceptibility of Bacteroides spp. to this agent. We report a case of metronidazole-resistant Bacteroides fragilis in the United States and demonstrate the presence of the nimA gene, encoding a nitroreductase previously shown to mediate resistance to 5-nitroimidazole antimicrobial agents in B. fragilis strains from Europe and Africa. Because clinical failures in Bacteroides infections have been associated with the use of inactive antimicrobial agents, clinicians need to be aware of the possibility of metronidazole-resistant B. fragilis strains in the United States and the importance of susceptibility testing in selected situations.
19
Kenneth E. Aldridge, Deborah Ashcraft, K M Cambre et al. · Antimicrobial Agents and Chemotherapy · 2001 · 232 citations · Full text
M. Hong Nguyen, Victor L. Yu, Arthur J. Morris et al. · Clinical Infectious Diseases · 2000 · 214 citations · Full text
David R. Snydman, N V Jacobus, L. A. McDermott et al. · Antimicrobial Agents and Chemotherapy · 1999 · 107 citations · Full text